FI107808B - Menetelmä verisuoni- sekä syöpäsairaudelle riskialttiin yksilön identifioimiseksi - Google Patents
Menetelmä verisuoni- sekä syöpäsairaudelle riskialttiin yksilön identifioimiseksi Download PDFInfo
- Publication number
- FI107808B FI107808B FI991836A FI19991836A FI107808B FI 107808 B FI107808 B FI 107808B FI 991836 A FI991836 A FI 991836A FI 19991836 A FI19991836 A FI 19991836A FI 107808 B FI107808 B FI 107808B
- Authority
- FI
- Finland
- Prior art keywords
- homocysteine
- concentration
- serum
- pgi
- risk
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 43
- 206010028980 Neoplasm Diseases 0.000 title claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 8
- 201000011510 cancer Diseases 0.000 title claims description 7
- 210000004204 blood vessel Anatomy 0.000 title claims 2
- 210000002966 serum Anatomy 0.000 claims description 43
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 35
- 108010047320 Pepsinogen A Proteins 0.000 claims description 29
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 23
- 229930003779 Vitamin B12 Natural products 0.000 claims description 19
- 235000019163 vitamin B12 Nutrition 0.000 claims description 19
- 239000011715 vitamin B12 Substances 0.000 claims description 19
- 239000012491 analyte Substances 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 7
- 239000000677 immunologic agent Substances 0.000 claims 1
- 229940124541 immunological agent Drugs 0.000 claims 1
- 238000003556 assay Methods 0.000 description 11
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 8
- 206010003694 Atrophy Diseases 0.000 description 7
- 230000037444 atrophy Effects 0.000 description 7
- 102000023732 binding proteins Human genes 0.000 description 6
- 108091008324 binding proteins Proteins 0.000 description 6
- 208000004300 Atrophic Gastritis Diseases 0.000 description 5
- 208000036495 Gastritis atrophic Diseases 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 108010066264 gastrin 17 Proteins 0.000 description 4
- GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 229940029329 intrinsic factor Drugs 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000195620 Euglena Species 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 description 2
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000005226 corpus cavernosum Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 2
- CKRJGDYKYQUNIM-UHFFFAOYSA-N 3-fluoro-2,2-dimethylpropanoic acid Chemical compound FCC(C)(C)C(O)=O CKRJGDYKYQUNIM-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000025216 Gastric adenocarcinoma and proximal polyposis of the stomach Diseases 0.000 description 1
- 206010017807 Gastric mucosal hypertrophy Diseases 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010020365 Homocystinuria Diseases 0.000 description 1
- 208000000239 Hypertrophic Gastritis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001134654 Lactobacillus leichmannii Species 0.000 description 1
- 101150019913 MTHFR gene Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000034525 Ménétrier disease Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 150000001867 cobalamins Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
- G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI991836A FI107808B (fi) | 1999-08-31 | 1999-08-31 | Menetelmä verisuoni- sekä syöpäsairaudelle riskialttiin yksilön identifioimiseksi |
| CNB008122261A CN1158389C (zh) | 1999-08-31 | 2000-08-30 | 一种用于鉴别有血管及癌症疾病患病风险的个体的方法 |
| RU2002107982/15A RU2247389C2 (ru) | 1999-08-31 | 2000-08-30 | Способ идентификации индивидуума с риском сосудистого и ракового заболевания |
| JP2001520901A JP2003508059A (ja) | 1999-08-31 | 2000-08-30 | 管疾患及び癌の危険性のある人を同定する方法 |
| PCT/FI2000/000733 WO2001016356A1 (en) | 1999-08-31 | 2000-08-30 | Method for identifying an individual at risk for vascular and cancer disease |
| EP00956556A EP1210452A1 (en) | 1999-08-31 | 2000-08-30 | Method for identifying an individual at risk for vascular and cancer disease |
| AU68456/00A AU6845600A (en) | 1999-08-31 | 2000-08-30 | Method for identifying an individual at risk for vascular and cancer disease |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI991836 | 1999-08-31 | ||
| FI991836A FI107808B (fi) | 1999-08-31 | 1999-08-31 | Menetelmä verisuoni- sekä syöpäsairaudelle riskialttiin yksilön identifioimiseksi |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI19991836L FI19991836L (fi) | 2001-02-28 |
| FI107808B true FI107808B (fi) | 2001-10-15 |
Family
ID=8555217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI991836A FI107808B (fi) | 1999-08-31 | 1999-08-31 | Menetelmä verisuoni- sekä syöpäsairaudelle riskialttiin yksilön identifioimiseksi |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1210452A1 (enExample) |
| JP (1) | JP2003508059A (enExample) |
| CN (1) | CN1158389C (enExample) |
| AU (1) | AU6845600A (enExample) |
| FI (1) | FI107808B (enExample) |
| RU (1) | RU2247389C2 (enExample) |
| WO (1) | WO2001016356A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2312356C2 (ru) * | 2005-12-28 | 2007-12-10 | Федеральное государственное лечебно-профилактическое учреждение "Научно-клинический центр охраны здоровья шахтеров" Федерального агентства по энергетике РФ | Способ оценки степени тяжести ишемического инсульта у лиц в возрасте до 50 лет |
| RU2413940C2 (ru) * | 2009-02-02 | 2011-03-10 | Государственное образовательное учреждение высшего профессионального образования Воронежская государственная технологическая академия | Способ определения витамина b12 в водных растворах |
| RU2453001C1 (ru) * | 2010-10-18 | 2012-06-10 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" | Способ коррекции гипергомоцистеин индуцированного дефицита оксида азота l-норвалином в эксперименте |
| CN114924016B (zh) * | 2022-04-28 | 2024-03-08 | 中国医学科学院北京协和医院 | 同时检测硫酸化及未硫酸化胃泌素g17的方法及其检测试剂盒 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI97304C (fi) * | 1994-11-16 | 1996-11-25 | Locus Genex Oy | Menetelmä mahasyövän riskin seulonnaksi |
-
1999
- 1999-08-31 FI FI991836A patent/FI107808B/fi active
-
2000
- 2000-08-30 CN CNB008122261A patent/CN1158389C/zh not_active Expired - Lifetime
- 2000-08-30 RU RU2002107982/15A patent/RU2247389C2/ru active
- 2000-08-30 WO PCT/FI2000/000733 patent/WO2001016356A1/en not_active Ceased
- 2000-08-30 AU AU68456/00A patent/AU6845600A/en not_active Abandoned
- 2000-08-30 JP JP2001520901A patent/JP2003508059A/ja active Pending
- 2000-08-30 EP EP00956556A patent/EP1210452A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001016356A1 (en) | 2001-03-08 |
| EP1210452A1 (en) | 2002-06-05 |
| CN1158389C (zh) | 2004-07-21 |
| FI19991836L (fi) | 2001-02-28 |
| JP2003508059A (ja) | 2003-03-04 |
| AU6845600A (en) | 2001-03-26 |
| CN1371427A (zh) | 2002-09-25 |
| RU2247389C2 (ru) | 2005-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1298536C (en) | Assay for sulfhydryl amino acids and methods for detecting and distinguishing cobalamin and folic acid deficiency | |
| Sabbioni et al. | The aflatoxin—lysine adduct quantified by high-performance liquid chromatography from human serum albumin samples | |
| UBBINK | Assay methods for the measurement of total homocyst (e) ine in plasma | |
| JP2009520957A (ja) | 便試料中のヘモグロビンおよびｍ２−ｐｋを測定することによる結腸直腸癌の評価方法 | |
| US20050064422A1 (en) | Polypeptide quantitation | |
| US20100297680A1 (en) | Methods for assessing the risk for development of cardiovascular disease | |
| Peng et al. | Optimizing proteolytic digestion conditions for the analysis of serum albumin adducts of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine, a potential human carcinogen formed in cooked meat | |
| Lavoinne et al. | Serum cardiac troponins I and T in early posttraumatic rhabdomyolysis | |
| Maldonado et al. | Simultaneous electrochemical measurement method of histamine and Nτ-methylhistamine by high-performance liquid chromatography–amperometry with o-phthalaldehyde–sodium sulfite derivatization | |
| Welp et al. | Development and validation of a high throughput direct radioimmunoassay for the quantitative determination of serum and plasma melatonin (N-acetyl-5-methoxytryptamine) in mice | |
| Harrington | Methods for assessment of vitamin B12 | |
| FI107808B (fi) | Menetelmä verisuoni- sekä syöpäsairaudelle riskialttiin yksilön identifioimiseksi | |
| Sheabar et al. | Quantitative analysis of aflatoxin-albumin adducts | |
| US20030124616A1 (en) | Homocysteinylated transthyretin | |
| US20240410908A1 (en) | Biomarker for diagnosing cancer and use thereof | |
| Manolov et al. | Serum hepcidin levels in Bulgarian population | |
| Blanco-Vaca et al. | Comparison of the Abbott IMx® and a high-performance liquid chromatography method for measuring total plasma homocysteine | |
| CN112595851A (zh) | 一种强稳定性的同型半胱氨酸测定试剂盒及其制备方法 | |
| RU2224258C2 (ru) | Способ идентификации индивидуума, у которого существует риск необратимых неврологических повреждений, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и витамина в12 | |
| Tateishi et al. | Stability of bombesin in serum, plasma, urine, and culture media. | |
| JP2003508059A5 (enExample) | ||
| Finglas et al. | Validity of dual-label stable isotopic protocols and urinary excretion ratios to determine folate bioavailability from food | |
| Mourvaki et al. | Performance comparison of three assay methods used in fasting and postmethionine load plasma homocysteine determinations from patients with vascular disease | |
| US7727972B2 (en) | Methods for determining absorption of cobalamin or analogues thereof | |
| SHINOGI et al. | Measurement of metallothionein in rat tissues by a chromatographic method using the fluorometry of thiol groups |